NewLink Genetics Corp., an Iowa biopharmaceutical company focusing on immunotherapeutic products for improved cancer treatment options, has reportedly established the expected range of its initial public offering (IPO) of 5.5 million shares at $10 to $12 a share. Expecting to raise about $53.4 million, the company said it hopes to use the funds to complete testing of its pancreatic cancer drug HyperAcute Pancreas, which, currently in late-stage trials, has received fast-track and orphan-drug designations from the Food and Drug Administration. The funds will also be used for other research and working capital. According to its Website, the company is involved in earlierphase trials for lung cancer and melanoma treatments. See Wall Street Journal, October 26, 2011.